Pérez Oliver, Bracho Gustavo, Lastre Miriam, Zayas Caridad, González Domingo, Gil Danay, del Campo Judith, Acevedo Reinaldo, Taboada Carlos, Rodríguez Tamara, Fajardo María E, Sierra Gustavo, Campa Concepción, Mora Nestor, Barberá Ramón, Solís Rosa L
Immunology Department, Finlay Institute, P.O. Box 16017, Havana, Cuba.
Vaccine. 2006 Apr 12;24 Suppl 2:S2-52-3. doi: 10.1016/j.vaccine.2005.01.127.
Proteoliposome (PL) has been recently used as a protective intramuscular (i.m.) anti-meningococcal BC vaccine. It induces a preferential Th 1 type of immune response. Nevertheless, mucosal protection is mainly mediated by IgA antibody response, which is not usually induced by i.m. vaccination route. IgA antibody production needs the stimulation of Th3 subpopulation, which is also related to the induction of small dose tolerance. We hypothesized that PL-derived Cochleate can induce a specific mucosal IgA and systemic IgG antibody responses. We could show that mice immunized with two or three intranasal doses of PL-derived Cochleate developed significantly increased levels of local anti PL IgA and systemic IgG antibody responses. Thus, our results suggest that PL-derived Cochleate can be used as a promising immunomodulator and delivery system for the development of mucosal, particularly nasal vaccines.
